Skip to main content
. 2012 May 24;122(6):2018–2031. doi: 10.1172/JCI46231

Figure 5. Viability of human and mouse fibroblasts exposed to BIM SAHBA peptides.

Figure 5

WS1 human fibroblasts showed no response to BIM SAHBA peptides (0–10 μM), as assessed by (A) viability and (B) caspase-3/7 activation assays performed at 24 and 6 hours after treatment, respectively. Staurosporine (100 nM), which impaired viability and induced caspase-3/7 activation, served as a positive control. Adherent WT and DKO MEFs likewise showed no response to BIM SAHBA treatment in this dose range, as assessed by (C and E) viability and (D and F) caspase-3/7 activation assays. As a positive control, (C and D) staurosporine (100 nM) triggered caspase-3/7 activation and reduced viability of WT MEFs, (E and F) whereas DKO MEFs exhibited relative resistance to staurosporine with no caspase-3/7 activation, as reported previously (50). Data are mean ± SEM for experiments performed at least in triplicate.